重症新冠肺炎患者诊疗的研究进展
袁婷婷 （ 北京大学国际医院核医学科 ）
王荣福 （ 1.北京大学国际医院核医学科 2.北京大学第一医院核医学科 ）
https://doi.org/10.37155/2661-4766-0203-2Abstract
新型冠状病毒传播性强，总体死亡率偏低，但重症患者死亡率较高，与轻症患者对比，其病情进展迅速，影像表现典型，多项实验室指标异常更为显著，部分患者需重症监护室治疗、机械通气，早期诊断、密切关注病情变化和综合治疗非常重要。
Keywords
新型冠状病毒肺炎; 重症患者; 临床特征Full Text
PDFReferences
[1] Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study[J]. Lancet Respir Med,2020,8(5):475-481.
[2] Guan W-J, Ni Z-Y, Hu Y, et al. Clinical Characteristics of Coronavirus Disease 2019 in China[J]. N Engl J Med,2020,382(18):1708-1720.
[3] Li Q, Guan X, Wu P, et al. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia[J]. N Engl J Med,2020,382(13):1199-1207.
[4]曹丰,刘传斌,李天志.老年人新型冠状病毒肺炎防控的权威指南荟萃[J].中华老年多器官疾病杂志,2020,19(02):81-84.
[5] Tian S, Hu N, Lou J, et al. Characteristics of COVID-19 infection in Beijing[J]. J Infect,2020,80(4):401-406.
[6] 袁婧,孙艳雨,左玉洁,等.重庆市223例新型冠状病毒肺炎患者的临床特征分析[J].西南大学学报(自然科学版),2020,42(3):1-7.
[7] Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China[J]. Lancet (London, England), 2020,395(10223): 497-506.
[8]中华预防医学会新型冠状病毒肺炎防控专家组.新型冠状病毒肺炎流行病学特征的最新认识[J].中国病毒病杂志:1-7.
[9]国家卫生健康委办公厅,国家中医药管理局办公室.关于印发新型冠状病毒肺炎诊疗方案(试行第七版)的通知[EB/OL]. http://www.nhc.gov.cn/yzygj/s7653p/202003/46c9294a7dfe4cef80dc7f5912eb1989.shtml, 2020-03-03.
[10]中国疾病预防控制中心新型冠状病毒肺炎应急响应机制流行病学组.新型冠状病毒肺炎流行病学特征分析[J].中华流行病学杂志, 2020,41(2):145-151.
[11] Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China[J]. JAMA,2020,382(18):1708-1720.
[12]曹佳,周军,廖星男,等.老年新型冠状病毒肺炎患者的临床特点与CT征象[J].武汉大学学报(医学版),2020(03):1-4.
[13] Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study[J]. Lancet (London, England),2020,395(10223):507-513.
[14] Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome[J]. Lancet Respir Med,2020,8(4):420-422.
[15] Kuba K, Imai Y, Rao S, et al. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury[J]. Nat Med, 2005, 11(8):875-879.
[16] Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin[J]. Nature,2020,579(7798):270-273.
[17]刘映霞,杨扬,张聪.新型冠状病毒(2019-nCoV)感染患者肺损伤相关的临床及生化指标研究[J].中国科学:生命科学,2020,50(03):258-269.
[18] Zumla A, Hui DS, Azhar EI, et al. Reducing mortality from 2019-nCoV: host-directed therapies should be an option[J]. Lancet,2020,395(10224): e35-e36.
[19] Lin YC, Jheng-Wei L, Mai-Szu W, et al. Effects of calcium channel blockers comparing to angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with hypertension and chronic kidney disease stage 3 to 5 and dialysis: A systematic review and meta-analysis[J]. PLoS One,2017,12(12): e0188975-.
[20] Crackower MA, Sarao R, Oudit GY, et al. Angiotensin-converting enzyme 2 is an essential regulator of heart function[J]. Nature,2002,417(6891):822-828.
[21] Li W, Moore MJ, Vasilieva N, et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus[J]. Nature,2003,426(6965):450-454.
[22] Zou X, Chen K, Zou J, et al. Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection[J]. Front Med,2020,14(2):185-192.
[23] 陈碧珊,陈吉生.托珠单抗在新型冠状病毒肺炎的应用研究探讨[J].今日药学2020,30(04):225-228.
[24] Chung M, Bernheim A, Mei X, et al. CT Imaging Features of 2019 Novel Coronavirus (2019-nCoV)[J]. Radiology,295(1):202-207.
[25] Xiong Y, Sun D, Liu Y, et al. Clinical and High-Resolution CT Features of the COVID-19 Infection: Comparison of the Initial and Follow-up Changes[J]. Invest Radiol,2020,55(6):332-339.
[26] 程克斌,魏明,沈虹,等.普通型和重型新型冠状病毒肺炎康复患者463例临床特征分析[J/OL].上海医学:
1-15[2020-06-05].http://kns.cnki.net/kcms/detail/31.1366.r.20200312.1254.004.html.
[27] Booth CM, Matukas LM, Tomlinson GA, et al. Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area[J]. JAMA, 2003,289(21):2801-2809.
[28] 何超,江虹,谢轶.新型冠状病毒肺炎诊治的实验室检验路径探讨[J].中国呼吸与危重监护杂志,2020,19(02):125-127.
[29] 闵瑞,刘洁,代喆,等.新型冠状病毒肺炎发病机制及临床研究进展[J]. 中华医院感染学杂志,2020,30(08):1171-1176.
[30] 王玉光,齐文升,马家驹.新型冠状病毒肺炎中医临床特征与辨证治疗初探[J].中医杂志,2020,61(04):281-285.
[31] 孙惠敏,徐锋,张玲,等.连花清咳颗粒治疗轻型、普通型新型冠状病毒肺炎临床疗效研究[J/OL].中国实验方剂学杂志:1-8[2020-06-05].https://doi.org/10.13422/j.cnki.syfjx.20201438.
[32] 刘明杰,陶杨,万鹏,等.薛氏扶阳逐湿汤化裁治疗36例核酸转阴困难新型冠状病毒肺炎患者的临床观察[J]. 西南大学学报(自然科学版),2020,42(05):31-35.
[2] Guan W-J, Ni Z-Y, Hu Y, et al. Clinical Characteristics of Coronavirus Disease 2019 in China[J]. N Engl J Med,2020,382(18):1708-1720.
[3] Li Q, Guan X, Wu P, et al. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia[J]. N Engl J Med,2020,382(13):1199-1207.
[4]曹丰,刘传斌,李天志.老年人新型冠状病毒肺炎防控的权威指南荟萃[J].中华老年多器官疾病杂志,2020,19(02):81-84.
[5] Tian S, Hu N, Lou J, et al. Characteristics of COVID-19 infection in Beijing[J]. J Infect,2020,80(4):401-406.
[6] 袁婧,孙艳雨,左玉洁,等.重庆市223例新型冠状病毒肺炎患者的临床特征分析[J].西南大学学报(自然科学版),2020,42(3):1-7.
[7] Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China[J]. Lancet (London, England), 2020,395(10223): 497-506.
[8]中华预防医学会新型冠状病毒肺炎防控专家组.新型冠状病毒肺炎流行病学特征的最新认识[J].中国病毒病杂志:1-7.
[9]国家卫生健康委办公厅,国家中医药管理局办公室.关于印发新型冠状病毒肺炎诊疗方案(试行第七版)的通知[EB/OL]. http://www.nhc.gov.cn/yzygj/s7653p/202003/46c9294a7dfe4cef80dc7f5912eb1989.shtml, 2020-03-03.
[10]中国疾病预防控制中心新型冠状病毒肺炎应急响应机制流行病学组.新型冠状病毒肺炎流行病学特征分析[J].中华流行病学杂志, 2020,41(2):145-151.
[11] Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China[J]. JAMA,2020,382(18):1708-1720.
[12]曹佳,周军,廖星男,等.老年新型冠状病毒肺炎患者的临床特点与CT征象[J].武汉大学学报(医学版),2020(03):1-4.
[13] Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study[J]. Lancet (London, England),2020,395(10223):507-513.
[14] Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome[J]. Lancet Respir Med,2020,8(4):420-422.
[15] Kuba K, Imai Y, Rao S, et al. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury[J]. Nat Med, 2005, 11(8):875-879.
[16] Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin[J]. Nature,2020,579(7798):270-273.
[17]刘映霞,杨扬,张聪.新型冠状病毒(2019-nCoV)感染患者肺损伤相关的临床及生化指标研究[J].中国科学:生命科学,2020,50(03):258-269.
[18] Zumla A, Hui DS, Azhar EI, et al. Reducing mortality from 2019-nCoV: host-directed therapies should be an option[J]. Lancet,2020,395(10224): e35-e36.
[19] Lin YC, Jheng-Wei L, Mai-Szu W, et al. Effects of calcium channel blockers comparing to angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with hypertension and chronic kidney disease stage 3 to 5 and dialysis: A systematic review and meta-analysis[J]. PLoS One,2017,12(12): e0188975-.
[20] Crackower MA, Sarao R, Oudit GY, et al. Angiotensin-converting enzyme 2 is an essential regulator of heart function[J]. Nature,2002,417(6891):822-828.
[21] Li W, Moore MJ, Vasilieva N, et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus[J]. Nature,2003,426(6965):450-454.
[22] Zou X, Chen K, Zou J, et al. Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection[J]. Front Med,2020,14(2):185-192.
[23] 陈碧珊,陈吉生.托珠单抗在新型冠状病毒肺炎的应用研究探讨[J].今日药学2020,30(04):225-228.
[24] Chung M, Bernheim A, Mei X, et al. CT Imaging Features of 2019 Novel Coronavirus (2019-nCoV)[J]. Radiology,295(1):202-207.
[25] Xiong Y, Sun D, Liu Y, et al. Clinical and High-Resolution CT Features of the COVID-19 Infection: Comparison of the Initial and Follow-up Changes[J]. Invest Radiol,2020,55(6):332-339.
[26] 程克斌,魏明,沈虹,等.普通型和重型新型冠状病毒肺炎康复患者463例临床特征分析[J/OL].上海医学:
1-15[2020-06-05].http://kns.cnki.net/kcms/detail/31.1366.r.20200312.1254.004.html.
[27] Booth CM, Matukas LM, Tomlinson GA, et al. Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area[J]. JAMA, 2003,289(21):2801-2809.
[28] 何超,江虹,谢轶.新型冠状病毒肺炎诊治的实验室检验路径探讨[J].中国呼吸与危重监护杂志,2020,19(02):125-127.
[29] 闵瑞,刘洁,代喆,等.新型冠状病毒肺炎发病机制及临床研究进展[J]. 中华医院感染学杂志,2020,30(08):1171-1176.
[30] 王玉光,齐文升,马家驹.新型冠状病毒肺炎中医临床特征与辨证治疗初探[J].中医杂志,2020,61(04):281-285.
[31] 孙惠敏,徐锋,张玲,等.连花清咳颗粒治疗轻型、普通型新型冠状病毒肺炎临床疗效研究[J/OL].中国实验方剂学杂志:1-8[2020-06-05].https://doi.org/10.13422/j.cnki.syfjx.20201438.
[32] 刘明杰,陶杨,万鹏,等.薛氏扶阳逐湿汤化裁治疗36例核酸转阴困难新型冠状病毒肺炎患者的临床观察[J]. 西南大学学报(自然科学版),2020,42(05):31-35.
Copyright © 2020 袁婷婷, 王荣福
Publishing time:2020-06-28
This work is licensed under a Creative Commons Attribution 4.0 International License
Email
Location